Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Protagonist Therapeutics announced its participation in the 7th Annual Evercore ISI HealthCONx Conference scheduled for December 3-5, 2024, in Coral Gables, Florida. Dinesh V. Patel, Ph.D., President and CEO, will engage in a fireside chat on Tuesday, December 3 at 8:45 A.M. ET. The presentation will be accessible via webcast, and the company will also conduct one-on-one meetings during the conference. A replay of the fireside chat will remain available on the company's Investor Relations Events and Presentations webpage for one year after the event.
Protagonist Therapeutics ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore ISI HealthCONx, in programma dal 3 al 5 dicembre 2024, a Coral Gables, Florida. Dinesh V. Patel, Ph.D., Presidente e CEO, parteciperà a una chiacchierata informale martedì 3 dicembre alle 8:45 A.M. ET. La presentazione sarà accessibile tramite webcast, e l'azienda condurrà anche incontri individuali durante la conferenza. Una registrazione della chiacchierata informale sarà disponibile sulla pagina degli eventi e presentazioni per gli investitori dell'azienda per un anno dopo l'evento.
Protagonist Therapeutics anunció su participación en la 7ª Conferencia Anual Evercore ISI HealthCONx, programada para el 3 al 5 de diciembre de 2024, en Coral Gables, Florida. Dinesh V. Patel, Ph.D., Presidente y CEO, participará en un chat informal el martes 3 de diciembre a las 8:45 A.M. ET. La presentación estará disponible a través de webcast, y la empresa también llevará a cabo reuniones uno a uno durante la conferencia. Una grabación del chat informal estará disponible en la página de Eventos y Presentaciones para Inversores de la empresa durante un año después del evento.
프로타고니스트 테라퓨틱스는 2024년 12월 3일부터 5일까지 플로리다주 코랄 게이블스에서 열리는 제7회 에버코어 ISI 헬스컨퍼런스에 참여할 것이라고 발표했습니다. 디네시 V. 파텔, Ph.D., 대통령이자 CEO는 12월 3일 화요일 오전 8시 45분 ET에 화상 대화에 참여합니다. 발표는 웹캐스트를 통해 접근 가능하며, 회사는 또한 컨퍼런스 동안 1:1 미팅을 진행할 예정입니다. 화상 대화의 재생은 행사 후 1년 동안 회사의 투자자 관계 이벤트 및 프레젠테이션 웹페이지에서 이용 가능합니다.
Protagonist Therapeutics a annoncé sa participation à la 7e Conférence Annuelle Evercore ISI HealthCONx, qui se déroulera du 3 au 5 décembre 2024 à Coral Gables, en Floride. Dinesh V. Patel, Ph.D., Président et CEO, participera à une discussion informelle le mardi 3 décembre à 8h45 ET. La présentation sera accessible par webcast, et l'entreprise tiendra également des réunions en tête-à-tête durant la conférence. Un enregistrement de la discussion sera disponible sur la page Événements et Présentations des Relations Investisseurs de l'entreprise pendant un an après l'événement.
Protagonist Therapeutics gab seine Teilnahme an der 7. jährlichen Evercore ISI HealthCONx-Konferenz bekannt, die vom 3. bis 5. Dezember 2024 in Coral Gables, Florida, stattfinden wird. Dinesh V. Patel, Ph.D., Präsident und CEO, wird am Dienstag, den 3. Dezember um 8:45 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Webcast zugänglich sein, und das Unternehmen wird während der Konferenz auch Einzelgespräche führen. Eine Aufnahme des informellen Gesprächs wird ein Jahr nach der Veranstaltung auf der Webseite für Investorenbeziehungen des Unternehmens verfügbar sein.
- None.
- None.
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference taking place December 3-5, 2024 in Coral Gables, Florida. The Company will also participate in one-on-one meetings.
7th Annual Evercore ISI HealthCONx Conference - December 3-5, 2024
Format: Fireside Chat
Day/Time: Tuesday, December 3 at 8:45 A.M. ET
Webcast: https://wsw.com/webcast/evercore44/ptgx/2402505
If you are interested in meeting with the Protagonist team during the conference, please reach out to your Evercore representative.
A replay of the fireside will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (JNJ-2113, formerly PN-235), is the first targeted oral peptide designed to selectively block the IL-23 receptor,which underpins the inflammatory response in moderate-to-severe plaque PsO and other IL-23-mediated diseases. Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells. Icotrokinra is licensed to Johnson & Johnson and is currently in Phase 3 development for psoriasis and is nearing completion of Phase 2b development for ulcerative colitis. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17, hepcidin mimetic, and anti-obesity programs.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Contact Information
Corey Davis Ph.D.
Investor Relations Contact - LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Virginia Amann
Media Relations Contact - ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1
SOURCE: Protagonist Therapeutics
View the original press release on accesswire.com
FAQ
When is Protagonist Therapeutics (PTGX) presenting at the Evercore ISI HealthCONx Conference 2024?
Where can I watch Protagonist Therapeutics (PTGX) Evercore Conference presentation?
What type of presentation will Protagonist Therapeutics (PTGX) give at the Evercore Conference 2024?
Where is the 2024 Evercore ISI HealthCONx Conference being held?
